ライフサイエンスコーパス: fluoxetine

1 d 250 mg of imipramine equivalents (50 mg of fluoxetine).

2 better response to two SSRIs (paroxetine and fluoxetine).

3 in regulation of BDNF expression induced by fluoxetine.

4 C optogenetic stimulation and is reversed by fluoxetine.

5 the selective serotonin reuptake inhibitor, fluoxetine.

6 ement in the sensitivity of the electrode to fluoxetine.

7 th injections, and chronic SSRI with dietary fluoxetine.

8 ng the reproductive phenotype attained under fluoxetine.

9 GR signalling and the therapeutic action of fluoxetine.

10 progeny of WT dams given the SERT antagonist fluoxetine.

11 of type I NSCs was unchanged in response to fluoxetine.

12 stress and the effects of the antidepressant fluoxetine.

13 were found to be the key residues in binding fluoxetine.

14 vely influenced by postnatal, but not adult, fluoxetine.

15 ent the behavioral and neurogenic effects of fluoxetine.

16 s and reversed by systemic administration of fluoxetine.

17 enesis abolish the antidepressant effects of fluoxetine.

18 ity and enhancing the behavioral response to fluoxetine.

19 ted by the selective 5-HT reuptake inhibitor fluoxetine.

20 idepressant-like activities as observed with fluoxetine.

21 BDNF in hippocampus suppressed the effect of fluoxetine.

22 reatment with desipramine (50-200 mg/day) or fluoxetine (10-40 mg/day) after a 1-week placebo lead-in

23 ily oral treatment of either amiloride 5 mg, fluoxetine 20 mg, riluzole 50 mg, or placebo for 96 week

24 Of these, 115 patients were taking fluoxetine (20 mg/day) for >/=2 months, and 121 patients

25 (N=8) of each group was randomly assigned to fluoxetine (3 mg/kg) or placebo for 1 year.

26 ceive 3 weeks of oral dosing with placebo or fluoxetine, 40 mg per day.

27 with either agomelatine (40 mg/kg, i.p.) or fluoxetine (5 mg/kg, i.p.) for 21 d.

28 long-term treatment with the antidepressants fluoxetine (5 mg/kg/day) and desipramine (10 mg/kg/day),

29 the selective serotonin reuptake inhibitor, fluoxetine (5 or 25 mg/L), commonly known as Prozac(R),

30 genetic deletion of Slc6a4 or treatment with Fluoxetine, a 5-HT reuptake inhibitor, restored normal b

31 Follow-up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SS

32 Fluoxetine, a selective serotonin reuptake inhibitor, ha

33 to quantify uptake and biological effects of fluoxetine, a selective serotonin reuptake inhibitor, in

34 vestigated the Nav1.5 blocking properties of fluoxetine, a selective serotonin reuptake inhibitor.

35 Long-term treatment of Hoxb8 mutants with fluoxetine, a serotonin reuptake inhibitor, reduces exce

36 Consistent with this idea, the SERT blocker fluoxetine abolished methylphenidate-induced locomotor a

37 the selective serotonin reuptake inhibitor, fluoxetine, abrogated behavioural impairments and restor

38 and 50 mug/L fluoxetine were able to reduce fluoxetine accumulation from 94 to 120 hpf.

39 ion with fluoxetine restores the efficacy of fluoxetine actions on D1 receptor expression and behavio

40 Fluoxetine administered to juvenile monkeys upregulates

41 This study examined the long-term effects of fluoxetine administered to juvenile rhesus monkeys who,

42 Unexpectedly, Fluoxetine administration was associated with respirator

43 be taken into consideration when prescribing fluoxetine alone or in association with other drugs that

44 Fluoxetine also resulted in significantly less anxiety a

45 ound in reclaimed wastewater: carbamazepine, fluoxetine, amitriptyline, and lamotrigine.

46 P450 enzymes and continuous accumulation of fluoxetine and 11 fluoxetine metabolites.

47 n removal in septal subregions, whereas both fluoxetine and a dopamine transporter blocker depress re

48 ry indicated that the observed uptake in the fluoxetine and carbamazepine treatments was due to the p

49 BT, fluoxetine, or joint treatment with both fluoxetine and CBT.

50 SERT Met172 mice are insensitive to chronic fluoxetine and citalopram administration in the novelty

51 n the tail suspension and forced swim tests, fluoxetine and citalopram fail to reduce immobility in S

52 the actions of two widely prescribed SSRIs, fluoxetine and citalopram, in tests sensitive to acute a

53 good-quality studies of fluoxetine, combined fluoxetine and cognitive behavioral therapy, escitalopra

54 Fluoxetine and desipramine reversed lower, but not highe

55 The authors compared the effectiveness of fluoxetine and desipramine treatment in a prospective do

56 ions and reasonable predictions of uptake of fluoxetine and diclofenac from a sediment.

57 the selective serotonin reuptake inhibitors fluoxetine and escitalopram.

58 y reduced primary anxiety symptoms more than fluoxetine and improved remission more than sertraline.

59 We treated animals with fluoxetine and induced ovulation with a single injection

60 DIVS6) significantly reduced the affinity of fluoxetine and its frequency-dependent inhibition.

61 Additionally, depuration of fluoxetine and its metabolites from 96 to 120 hpf was in

62 fertilization (hpf), and the accumulation of fluoxetine and its metabolites was analyzed over time.

63 During depuration, accumulation of fluoxetine and most metabolites was clearly reduced, and

64 We find that the selectivity of fluoxetine and nisoxetine, a NET selective structural co

65 ed in the order carbamazepine < diclofenac < fluoxetine and orlistat.

66 evaluated a sequential treatment strategy of fluoxetine and relapse-prevention cognitive-behavioral t

67 e inhibitors (SSRIs: citalopram, paroxetine, fluoxetine and sertraline) in a retrospective cohort mai

68 We further demonstrate that the SSRIs, fluoxetine and sertraline, directly suppress TIDA neuron

69 We first determined that the SSRI fluoxetine and the nicotinic partial agonist cytisine ha

70 The 5-HT uptake inhibitor fluoxetine and the norepinephrine uptake inhibitor desip

71 ation of the antidepressants desipramine and fluoxetine and the preparation of an aza analogue of the

72 Both fluoxetine and thioridazine inhibited efflux in P. mirab

73 al for drugs already used in human medicine (fluoxetine and thioridazine) to act as EPIs in P. mirabi

74 l agents, including duloxetine, atomoxetine, fluoxetine and tolterodine.

75 oach for two pharmaceuticals (diclofenac and fluoxetine) and one personal care product ingredient (tr

76 uman intravenous immunoglobulin (hIVIG), (2) fluoxetine, and (3) dexamethasone.

77 Furthermore, escitalopram, fluoxetine, and cocaine induced a very similar pattern o

78 The drugs diclofenac, fluoxetine, and gemfibrozil belong to different pharmace

79 data are needed on the uptake of cimetidine, fluoxetine, and gemfibrozil, and other ionizable PPCPs,

80 of (14)C-labeled carbamazepine, diclofenac, fluoxetine, and orlistat in soil-earthworm systems.

81 otics (particularly lurasidone, olanzapine + fluoxetine, and quetiapine) and the anticonvulsant lamot

82 ortisone, IgG, valganciclovir, isoprinosine, fluoxetine, and various complementary medicines were inc

83 No EFr was observed for citalopram, fluoxetine, and venlafaxine despite almost complete atte

84 However, unlike fluoxetine, anxiolytic effects of RS67333 were already p

85 that the effects of both chondroitinase and fluoxetine are mediated by the neurotrophin receptor TRK

86 erotonin Reuptake Inhibitors (SSRIs) such as fluoxetine are widely prescribed to pregnant and breastf

87 effects of chronic treatment with the SSRI, fluoxetine, are abolished by mossy cell-specific knockou

88 TRKB C-terminal region, indicating that the fluoxetine-binding site in TRKB lies outside the TRKB:AP

89 We show that fluoxetine binds within the central substrate site of hu

90 We concluded that fluoxetine blocks Nav1.5 by binding to the class 1 antia

91 Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found t

92 o the selective serotonin reuptake inhibitor fluoxetine but not desipramine, a selective norepinephri

93 easure revealed that, compared with placebo, fluoxetine (but not CBT) was significantly more effectiv

94 tion in the spiked plasma samples as well as fluoxetine capsules.

95 In contrast to fluoxetine, citalopram treatment did not increase BLA eC

96 resistant depression (TRD) taking olanzapine/fluoxetine combination (OFC).

97 n (SD) changes in MADRS score for the light, fluoxetine, combination, and placebo groups were 13.4 (7

98 individual fair- and good-quality studies of fluoxetine, combined fluoxetine and cognitive behavioral

99 th autism spectrum disorders, treatment with fluoxetine compared with placebo resulted in significant

100 sh were exposed to environmentally realistic fluoxetine concentrations (measured average: 38 or 312 n

101 Embryos treated with fluoxetine continued to exhibit abnormal behavior upto 1

102 In the process, we confirmed that fluoxetine could improve the depression-like behaviors o

103 Fluoxetine decreased immobility in the forced swim test,

104 The antidepressants fluoxetine, desipramine and ketamine increased PKMzeta e

105 This sensor was used successfully for fluoxetine determination in the spiked plasma samples as

106 a noninactivating Nav1.5 mutant to show that fluoxetine displays open-channel block behavior.

107 Of note, fluoxetine disrupted the coupling between full-length TR

108 Antidepressant fluoxetine disrupts the interaction between TRKB and PTP

109 d that a single intraperitoneal injection of fluoxetine disrupts the interaction of several proteins

110 increase up to doses between 20 mg and 40 mg fluoxetine equivalents, and a flat to decreasing trend t

111 Doses of SSRIs were converted to fluoxetine equivalents.

112 lower licensed range between 20 mg and 40 mg fluoxetine equivalents.

113 hrough the higher licensed doses up to 80 mg fluoxetine equivalents.

114 Postnatal fluoxetine-evoked anxiety and depressive behavior, as we

115 h the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety and depressive behavior in ro

116 found no evidence for interactive effects of fluoxetine exposure and temperature stress on guppy beha

117 mergence of perturbed emotionality following fluoxetine exposure in early life.

118 Fluoxetine exposure resulted in increased male coercive

119 inhibition of CaMKII activity in NAc mimics fluoxetine exposure.

120 orters in T. sanguinis, which is reversed by fluoxetine exposure.

121 Behaviorally, chronic fluoxetine facilitated extinction retrieval in a manner

122 s revealed that, while degradation of chiral fluoxetine (FL) in river water occurs via non-enantiosel

123 ng SSRIs with lower QT-prolonging potential (fluoxetine, fluvoxamine, paroxetine, sertraline).

124 tes the transformation of the antidepressant fluoxetine (FLX) by photo- and biodegradation and shows

125 d the selective serotonin reuptake inhibitor fluoxetine (FLX) have both been shown to have immunomodu

126 f the selective-serotonin reuptake inhibitor fluoxetine (FLX) in a chronic unpredictable stress model

127 (5-HT) (serotonin) reuptake inhibitor (SSRI) fluoxetine (Flx) is ineffective as a prophylactic, we hy

128 nd studied the effects of the antidepressant fluoxetine (FLX) on behavior, olfaction, and adult neuro

129 n contrast, the serotonin reuptake inhibitor fluoxetine (FLX) reduced immobility after 14, but not 5

130 , we examined whether adolescent exposure to fluoxetine (FLX), a selective serotonin reuptake inhibit

131 ssessed the long-term effects of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibit

132 We show here that fluoxetine (Flx), one of the most-prescribed SSRIs, acts

133 elective serotonin reuptake inhibitor (SSRI) fluoxetine (FLX), the active ingredient of the antidepre

134 del of psychosocial stress, and prevents the fluoxetine (FLX)-induced reversal of SDS-induced social

135 tion by treating rabbits with daily doses of fluoxetine for 2 wk and found that fluoxetine treatment

136 th major depression were treated openly with fluoxetine for 6 weeks.

137 ports the safety, tolerance, and efficacy of fluoxetine for hypochondriasis.

138 ho remained stable were randomized to OFC or fluoxetine for up to 27 weeks.

139 posed to 0.1, 1.0, 10, 50, and 5000 mug/L of fluoxetine from 48 to 120 h post-fertilization (hpf), an

140 plicated by early-life exposure to the SSRI, fluoxetine (from P2 to P14), that also causes anxiety/de

141 Furthermore, fluoxetine gave rise to a change in neuropsychology.

142 2 years), 109 completed the trial; 31 in the fluoxetine group and 21 in the placebo group dropped out

143 e from baseline to 16 weeks decreased in the fluoxetine group from 12.80 to 9.02 points (3.72-point d

144 ts in the amiloride group, seven [6%] in the fluoxetine group, 12 [11%] in the riluzole group, and 13

145 so showed nominal significance (P < 0.05) in fluoxetine group.

146 hole-brain voxel-wise analysis revealed that fluoxetine had a significant effect in the lateral tempo

147 artery thrombosis, and one patient assigned fluoxetine had a sudden death (primary cause) with multi

148 Fluoxetine had no effect on motor impairment or viral lo

149 Fluoxetine had no significant effect on the behavioral m

150 Fluoxetine has been recognized as one of the most toxic

151 for 3001-4500 mg compared with 1-1500 mg in fluoxetine hydrochloride dose equivalents).

152 ride, lidocaine hydrochloride, diazepam, and fluoxetine hydrochloride that meet U.S. Pharmacopeia sta

153 ive negative ion generator for 30 min/d plus fluoxetine hydrochloride, 20 mg/d); (3) combination ligh

154 oxetine hydrochloride, escitalopram oxalate, fluoxetine hydrochloride, mirtazapine, nortriptyline hyd

155 Dose-response curves of racemic fluoxetine (IC50 = 39 muM) and its optical isomers had a

156 mine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortrip

157 find that retreatment of PNFlx animals with fluoxetine in adulthood reversed the increased Hdac4 exp

158 t as a racemic mixture, which is typical for fluoxetine in dispensed formulations.

159 rences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse

160 The molecular model of fluoxetine in Nav1.5 was in agreement with mutational ex

161 irregularly high load of the antidepressant fluoxetine in raw wastewater (10.5 +/- 2.4 g d(-1)) was

162 Our research highlighted the importance of fluoxetine in regulating BDNF expression which could rep

163 growing evidence that the toxic potential of fluoxetine in surface waters is markedly influenced by i

164 We modeled oral SSRI treatment via fluoxetine in the water, in a regimen recapitulating cli

165 study investigated the biotransformation of fluoxetine in the zebrafish embryo - an aquatic model or

166 Further, because systemically administered fluoxetine increased aggression in females and substanti

167 osure to serotonin or the reuptake inhibitor fluoxetine increased runx1 expression and Flk1(+)/cMyb(+

168 Fluoxetine increases serotonin-immunoreactivity at low f

169 lective serotonin reuptake inhibitor (SSRI), fluoxetine, increases D1 receptor expression in mature g

170 ntidepressant-like and neurogenic effects of fluoxetine, indicating that 5-HT(4) receptor activation

171 nctional 5HT1ARs only in DG GCs responded to fluoxetine, indicating that 5HT1ARs in DG GCs are suffic

172 Chronic treatment with RS67333, similar to fluoxetine, induced anxiolytic/antidepressant-like activ

173 electrophysiological recordings showed that fluoxetine-induced increases in anandamide were associat

174 mechanism of antidepressant action, whereby fluoxetine induces some chromatin change at the CaMKIIal

175 Fluoxetine inhibited currents in a frequency-dependent m

176 and negative correlation between duration of fluoxetine intake and attachment loss (AL) (R(2) = -0.32

177 ent study is to investigate the influence of fluoxetine intake on periodontal parameters in patients

178 Logistic regression analysis revealed that fluoxetine intake was associated with a lower risk of ha

179 Furthermore, as fluoxetine is prescribed as one capsule per day, disposa

180 Fluoxetine is probably the best option to consider when

181 However, the binding orientation of fluoxetine is reversed in our experimentally supported m

182 Fluoxetine is widely used to treat depression, including

183 tine, a NET selective structural congener of fluoxetine, is controlled by residues in different regio

184 For the respective placebo, fluoxetine, light, and combination groups at the end poi

185 prescription data revealed a predicted daily fluoxetine load for the studied treatment works to be 0.

186 in the order of carbamazepine < diclofenac < fluoxetine < orlistat.

187 Recent work has shown that fluoxetine may exert an antidepressive effect through in

188 Studies suggest that fluoxetine may have adverse effects on offspring, presum

189 cause the apneas in Necdin-KO pups, and that fluoxetine may offer therapeutic benefits to PWS patient

190 ifted in favor of norfluoxetine, the primary fluoxetine metabolite in humans.

191 Norfluoxetine, a fluoxetine metabolite, had a higher affinity than fluoxe

192 continuous accumulation of fluoxetine and 11 fluoxetine metabolites.

193 Treating T. sanguinis with 5-HT or fluoxetine modulates its competitive colonization in the

194 or to placebo in the MADRS change score, but fluoxetine monotherapy (d = 0.24; 95% CI, -0.27 to 0.74)

195 ents were randomized (light monotherapy, 32; fluoxetine monotherapy, 31; combination therapy, 29; pla

196 ciated with continuing treatment with OFC or fluoxetine must be done based on individual patient need

197 Participants were randomized to receive fluoxetine (n = 75) or placebo (n = 71).

198 s were randomly allocated amiloride (n=111), fluoxetine (n=111), riluzole (n=111), or placebo (n=112)

199 tients were randomized 1:1 to OFC (N=221) or fluoxetine (N=223).

200 atients who were allocated amiloride (n=99), fluoxetine (n=96), riluzole (n=99), and placebo (n=99).

201 erotonin reuptake inhibitors (SSRIs) such as fluoxetine ((+/-)-N-methyl-gamma-[4-(trifluoromethyl)phe

202 e blunting of the DRN output, while the SSRI fluoxetine noticeably enhances DRN functional connectivi

203 G GCs and found that the effects of the SSRI fluoxetine on behavior and the hypothalamic-pituitary-ad

204 We conclude that the effect of fluoxetine on copulation-induced ovulation rate supports

205 CBs in mediating the facilitatory effects of fluoxetine on fear extinction has not been established.

206 investigated, and autoinhibitory effects of fluoxetine on phase I biotransformation were analyzed.

207 verexpression of BMP4 blocked the effects of fluoxetine on proliferation in the dentate gyrus and on

208 Our study showed that the effect of fluoxetine on proliferation is dependent upon the type a

209 1A) recapitulated or abolished the effect of fluoxetine on proliferation of type II NSCs and neurobla

210 Fluoxetine, one of the selective serotonin reuptake inhi

211 Coexposure of plants to carbamazepine and fluoxetine or amitriptyline decreased accumulation of th

212 ed by chronic, but not acute, treatment with fluoxetine or clomipramine.

213 ive 5-HT reuptake inhibitors (SSRIs) such as fluoxetine or escitalopram inhibit SERT and are currentl

214 (SL) baboons administered the antidepressant fluoxetine or vehicle.

215 gned to one of four treatments-placebo, CBT, fluoxetine, or joint treatment with both fluoxetine and

216 ISA experiments revealed that in addition to fluoxetine, other chemically diverse antidepressants, su

217 e significantly lower in participants taking fluoxetine (P <0.01).

218 inhibitors (SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, and sertraline), venlafaxine, or

219 based sensitivity likely as a consequence of fluoxetine partitioning to sediment.

220 Fluoxetine persistently upregulated SERT, but not 5-HT1A

221 Paradoxically, postnatal fluoxetine (PNFlx) induces persistent depression- and an

222 in the behavioral consequences of postnatal fluoxetine (PNFlx).

223 The conventional antidepressant fluoxetine produces rapid or delayed antidepressant effe

224 with norfluoxetine, the active metabolite of fluoxetine (Prozac) and a state-dependent blocker of TRE

225 to the pervasive pharmaceutical contaminant fluoxetine (Prozac) and acute temperature stress on repr

226 dult behavioral changes resulting from early fluoxetine (Prozac) exposure were different from those o

227 and radiopharmaceuticals including Claritin, fluoxetine (Prozac), and [(18) F]DAA1106 were synthesize

228 NET for the prototypical antidepressant drug fluoxetine (Prozac; Eli Lilly, Indianapolis, IN).

229 e found that peripartum exposure to 20 mg/kg fluoxetine reduced femoral bone mineral density and bone

230 Indeed, chronic fluoxetine reduces acetylation and increases lysine-9 di

231 ally, chronic exposure to the antidepressant fluoxetine reduces binding of DeltaFosB to the CaMKIIalp

232 In addition, fluoxetine reduces the membership of T. sanguinis in the

233 We propose that both chABC and fluoxetine reopen critical period-like plasticity in the

234 n young adult-born GCs (abGCs) showed normal fluoxetine responses.

235 Importantly, the antidepressant fluoxetine restores both adult neurogenesis and depressi

236 of a D1 receptor agonist in conjunction with fluoxetine restores the efficacy of fluoxetine actions o

237 Exposure to 5000 mug/L fluoxetine resulted in elevated 7-ethoxyresorufin-O-deet

238 5-hydroxytryptophan (serotonin precursor) or fluoxetine (reuptake inhibitor) increases serotonin bioa

239 of pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam).

240 Overexpression of CaMKII in NAc blocks fluoxetine's antidepressant effects in the chronic socia

241 possible mechanistic contribution of eCBs to fluoxetine's proextinction effects, we integrated bioche

242 aste electrode (CPE) in order to construct a fluoxetine selective sensor.

243 provide strong evidence that exogenous SSRI fluoxetine selectively increases serotonin-immunoreactiv

244 The serotonin reuptake inhibitor fluoxetine selectively suppresses serotonin removal in s

245 All test drugs evoke fluoxetine-sensitive efflux of [(3)H]5-HT from synaptoso

246 cal agents that affect human orgasm, such as fluoxetine, should also affect ovulation in animals with

247 oblast populations specifically responded to fluoxetine, showing increased proliferation; however, pr

248 Treatment of zebrafish embryos with fluoxetine significantly blocked the expression of multi

249 The high dose of fluoxetine significantly decreased anxiety-like behaviou

250 Fluoxetine specifically increased proliferation of NSCs

251 d the complete removal of the antidepressant fluoxetine spiked into urban wastewater at near-neutral

252 h the selective serotonin reuptake inhibitor fluoxetine suppressed BMP signaling in the adult mouse h

253 that norfluoxetine is the only metabolite of fluoxetine that accumulates in zebrafish embryos at envi

254 Finally, in the presence of 1 muM fluoxetine, the sensor was able to monitor a reduction i

255 ted with the quantitative GR activity during fluoxetine therapy; this highlights the temporal variabi

256 Importantly, unlike (S)-fluoxetine, these compounds are no longer neuroactive.

257 the most commonly prescribed formulation of fluoxetine, this increased load accounts for the disposa

258 High-quality evidence did not support use of fluoxetine to improve motor function.

259 g DT50s of parent compounds ranged from 0.5 (fluoxetine) to 306 days (carbamazepine), with 20 substan

260 A 5-HTT inhibitor, fluoxetine, treated animals also exhibited reduced reste

261 longer in OFC-treated patients compared with fluoxetine-treated patients (p<0.001).

262 attern of response: joint treatment > CBT or fluoxetine treatment > placebo treatment.

263 mpal neurogenesis in comparison with chronic fluoxetine treatment (18 mg/kg/day).

264 suggest a neurobiological mechanism by which fluoxetine treatment confers resilience to the chronic s

265 We also found that fluoxetine treatment could disassociate the MeCP2-CREB-B

266 Fluoxetine treatment in adulthood evokes antidepressant

267 Chronic fluoxetine treatment produced a significant and selectiv

268 doses of fluoxetine for 2 wk and found that fluoxetine treatment reduces the number of ovulations po

269 Compared with desipramine, fluoxetine treatment showed a more rapid reduction of HA

270 Compared with desipramine treatment, fluoxetine treatment was associated with a greater reduc

271 Fluoxetine treatment was associated with a larger whole

272 chronic stress, which was partly restored by fluoxetine treatment without affecting glucocorticoid se

273 ation between GR (S224) and (S232) following fluoxetine treatment, showing a molecular basis for horm

274 turn, contributes to the actions of chronic fluoxetine treatment, such as suppression of acute stres

275 fear memory that was abolished with chronic fluoxetine treatment.

276 ontextual fear memory, alleviated by chronic fluoxetine treatment.

277 d swim test behavior after social defeat and fluoxetine treatment.

278 vities were alleviated by the antidepressant fluoxetine treatment.

279 e elimination of (14)C for carbamazepine and fluoxetine treatments and partial elimination for orlist

280 d to be disrupted by both acute and repeated fluoxetine treatments.

281 As fluoxetine undergoes stereoselective metabolism within t

282 addition, a synthesis of the antidepressant fluoxetine using remote hydroxylation as a key step is p

283 placebo, 0.0% [95% CI -0.4 to 0.5; p=0.99]; fluoxetine vs placebo -0.1% [-0.5 to 0.3; p=0.86]; riluz

284 In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [

285 Three weeks of intervention with fluoxetine was associated with a 5.2% reduction in brain

286 In this observational study, use of fluoxetine was associated with lower BOP percentages and

287 Bioconcentration of fluoxetine was dependent on route of uptake, with filter

288 o-selective analysis showed the high load of fluoxetine was present as a racemic mixture, which is ty

289 The response of the MIP-CP electrode to fluoxetine was remarkably higher than the electrode, mod

290 For efficacy, only fluoxetine was statistically significantly more effectiv

291 both as monotherapy and in combination with fluoxetine, was efficacious and well tolerated in the tr

292 Embryos exposed to 10 and 50 mug/L fluoxetine were able to reduce fluoxetine accumulation f

293 Participants taking fluoxetine were further analyzed for correlation between

294 uding highly selective recognition sites for fluoxetine were synthesized, utilizing precipitation pol

295 ribavirin, pyrrolidine dithiocarbamate, and fluoxetine were tested for their capacity to abrogate CV

296 The antidepressant drug fluoxetine, which is known to promote TRKB phosphorylati

297 l-specific and cell type-specific effects of fluoxetine, which requires adult hippocampal neurogenesi

298 and Drug Administration (FDA)-approved drug fluoxetine-which also targets 2C-but has favorable chemi

299 Worms exposed to 10 mug L(-1), accumulated fluoxetine with a body burden over 270 times greater tha

300 etine metabolite, had a higher affinity than fluoxetine, with an IC50 of 29 muM.